Plant toxin hailed as ‘new weapon’ in antibiotic war against bacteria

Scientists say albicidin has allowed them to take a giant step forward to creating a powerful new range of antibacterial drugs

Scientists have discovered a plant toxin whose unique method of dispatching bacteria could be used to create a powerful new range of antibiotics. The prospect of developing new antibacterial drugs this way has been hailed by doctors, who have been warning for many years that the steady rise of multidrug-resistant pathogens such as E coli now presents a dangerous threat to healthcare across the planet.

The new antibiotic – albicidin – attacks bacteria in a completely different way to existing drugs, a group of British, German and Polish scientists have revealed in a paper recently published in the journal Nature Catalysis. This suggests a new route could be exploited to tackle bacterial disease, they say.

“We could not elicit any resistance towards albicidin in the laboratory,” said Dmitry Ghilarov, whose research group is based at the John Innes Centre in Norwich. “That is why we are really excited – because we think it will be very hard for bacteria to evolve resistance against albicidin-derived antibiotics.”

Albicidin is produced by a bacterial plant pathogen called Xanthomonas albilineans that triggers a devastating disease, known as leaf scald, in sugarcane. The pathogen uses albicidin to attack the plant, but it was also found, several decades ago, that it was highly effective at killing bacteria.

“The problem was that, at the time, we did not know exactly how albicidin attacked bacteria and so we could not use it as the basis of new antibiotics because these might have triggered all sorts of complications in the human body,” said Ghilarov. “We had to determine precisely how it killed bacteria before we could do that – and that is what we have now achieved.”

Working with scientists at the Technische Universität Berlin in Germany and at Jagiellonian University in Kraków, Poland, Ghilarov and his team used a series of advanced techniques to reveal how albicidin kills.

“Now we have a structural understanding, we can create modifications of albicidin to improve its efficacy and pharmacological properties,” said Ghilarov. “We believe this is one of the most exciting new antibiotic candidates in many years. It has extremely high effectiveness in small concentrations and is highly potent against pathogenic bacteria – even those resistant to the widely used antibiotics such as fluoroquinolones.”

The World Health Organization has warned that antibiotic resistance has become one of the biggest threats to global health, food security and development. The indiscriminate overuse of antibiotics has caused bacteria to develop resistance to them, resulting in the evolution of some strains of microbes that have become much harder to eliminate, which in turn has led to higher medical costs, prolonged hospital stays and increased mortality.

One recent study suggested that this problem is now killing about 3,500 people every day, with more than 1.2 million dying in 2019 as a direct result of antibiotic-resistant bacterial infections.

“One problem is that there is simply not enough research and development into new antibiotics by pharmaceutical companies,” said Prof Tony Maxwell, who is also based at the John Innes Centre. “New compounds used to come on the market all the time but that is no longer the case. Fewer and fewer big pharma companies are working on antibiotics and so fewer and fewer are being approved by western drug authorities. The problem is that you don’t make money out of antibiotics any more.

“On the other hand, there is nothing better for treating a bacterial disease than an antibiotic, so this work, which opens up a whole new range of drugs based on our new understanding of how albicidin works, has got to be good news. It may take years to create clinically effective versions but it does suggest we may have a new weapon in our armoury one day.”

This point was backed by Ghilarov. “To get things moving, the government needs to step in, as it did with vaccine development. It needs to provide incentives or set up a dedicated antibiotic development institute.”


Robin McKie Science editor

The GuardianTramp

Related Content

Article image
Antibiotic shortage puts patients at risk, doctors fear
Exclusive: supply problems with one of their most widely used drugs mean doctors are being forced to ration its use and switch to less desirable alternatives

Nicola Davis

01, Jul, 2017 @11:33 AM

Article image
Antibiotic resistance: Bacteria are winning the war | Frank Swain
The insidious spread of the latest form of antibiotic resistance is just one more sign that governments haven't grasped the gravity of the situation, writes Frank Swain

Frank Swain

07, Apr, 2011 @12:45 PM

Article image
Pfizer and AstraZeneca ‘highly effective’ against India Covid variant
A Public Health England study has revealed the vaccines can be up to 88% effective after a second dose

Robin McKie

22, May, 2021 @6:28 PM

Article image
Coronavirus app has changed the way the Isle of Wight sees itself
Islanders are coming to terms with unexpected publicity from the contact-tracing pilot project

Sally Perry

09, May, 2020 @12:55 PM

Article image
'The more vaccine projects we have, the better our chances'
Leading scientist warns of stumbles along the way to Covid-19 immunisation

Robin McKie

28, Mar, 2020 @8:06 PM

Article image
UK scientists look at reducing boosters to save vaccine for rest of the world
JCVI considers lower third jab dosage to release stocks for poorer nations

Michael Savage

22, Aug, 2021 @9:56 AM

Article image
Lessons from Covid can start a health revolution, says lab chief
Director of network that processed millions of tests says smart diagnostics could tackle other major diseases

James Tapper

17, Apr, 2022 @7:13 AM

Article image
Public health measures are key to curbing Covid in UK, say scientists
On the second anniversary of the first lockdown, experts including Wellcome Trust director Jeremy Farrar, outline what needs to be done to cope with pandemics

James Tapper and Michael Savage

20, Mar, 2022 @8:30 AM

Article image
Long Covid: ‘It’s a year since I’ve felt like myself’
There is fresh hope for those still suffering the effects of the virus after 12 months with £18.5m of new funding and 70 new NHS clinics

James Tapper

20, Feb, 2021 @5:28 PM

Article image
I’ve had my first vaccine jab. It gives me hope of liberation... but not yet
Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement

Robin McKie Science Editor

24, Jan, 2021 @7:00 AM